Document Detail


Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases.
MedLine Citation:
PMID:  23154557     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: : Asbestos-related malignant pleural mesothelioma is one of the most lethal tumor types. The advent of antimetabolite treatment as pemetrexed, introduced in the early 2000s, may have increased survival on a population basis. In this study, we have analyzed population-based incidence and survival data over the last 40 years.
METHODS: : Complete national data on 1686 patients from the Cancer Registry of Norway sampled from 1970 to 2009 are presented, with incidence rates in 5-year periods. Relative survival for 1 year and 3 years and median survival in 5-year intervals were calculated.
RESULTS: : The incidence of malignant pleural mesothelioma has been significantly and steadily increasing from 1970 until 2009, with 50 patients diagnosed in the period 1970-1974 and 377 diagnosed in 2005-2009. The incidence was highest among men in all time periods. A slight decline was observed in the last period. The 1-year survival rate increased from 20.7% to 44.0% during the period 1970-2009, whereas the 3-year survival rate remained below 10%. Median survival increased from 4.0 months in the first period to 9.3 months in the last period.
CONCLUSIONS: : The incidence of malignant pleural mesothelioma follows the curve of asbestos exposure with a 20- to 40-year lag. There has been a significant increase in survival, most likely because of earlier diagnosis and improvements in cytostatic treatment.
Authors:
Aslaug Helland; Steinar Solberg; Odd Terje Brustugun
Related Documents :
7790247 - The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the...
19373947 - Relapse patterns and related prognostic factors in patients with mobile tongue cancer t...
11115277 - Masses of the salivary gland region in children.
24375467 - Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged seco...
18362087 - Loose seeds vs. stranded seeds: a comparison of critical organ dosimetry and acute toxi...
8152247 - Phase i-ii trial of high dose ara-c, carboplatinum, etoposide and steroids in patients ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer     Volume:  7     ISSN:  1556-1380     ISO Abbreviation:  J Thorac Oncol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101274235     Medline TA:  J Thorac Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1858-61     Citation Subset:  IM    
Affiliation:
*Department of Oncology, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway; †Institute of Clinical Medicine, University of Oslo, Oslo, Norway; and ‡Department of Thoracic Surgery, Oslo University Hospital-Rikshospitalet, Oslo, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  E1B-55 kDa-Defective Adenoviruses Activate p53 in Mesothelioma and Enhance Cytotoxicity of Anticance...
Next Document:  Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the ...